Form 4: Aurinia CEO Peter Greenleaf Reports Tax-Related Stock Sale

Aurinia Pharmaceuticals CEO Peter Greenleaf reported the disposition of 100,171 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Peter Greenleaf, Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. (AUPH), reported a transaction involving the company's common stock.
• On February 20, 2026, Greenleaf disposed of 100,171 shares of common stock at a price of $14.4 per share.
• This disposition was a 'Tax Withholding' transaction (Code F), meaning the shares were withheld to satisfy tax obligations upon the vesting of restricted stock units.
• Following this transaction, Greenleaf beneficially owns 1,744,866 shares of Aurinia Pharmaceuticals Inc. common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related disposition following the vesting of restricted stock units, rather than a discretionary sale or purchase.

Positives

• The transaction indicates the vesting of restricted stock units, which often implies continued employment and performance-based compensation for the CEO.
• The CEO retains a significant beneficial ownership of 1,744,866 shares, aligning his interests with shareholders.

Negatives

• The disposition of shares, even for tax purposes, reduces the CEO's direct ownership slightly.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to RSU vesting and tax withholding, are common occurrences in the pharmaceutical industry as part of executive compensation packages. While this specific transaction is routine, the overall level of insider ownership and subsequent transactions can provide insights into management's confidence and long-term commitment to the company.

Comparison to Industry Standards

• This transaction is a standard practice for executives receiving equity compensation. For example, similar tax-related dispositions are frequently observed among executives at peer pharmaceutical companies like Biogen (BIIB) or Vertex Pharmaceuticals (VRTX) when their restricted stock units vest.
• The retention of a substantial number of shares post-transaction is consistent with typical executive compensation structures designed to align management interests with long-term shareholder value.

Related Party Transactions

• This filing details an insider transaction (CEO disposing of shares), which is a type of related party dealing. However, it's a standard compensation-related event rather than a unique related-party business transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact. The transaction is a routine part of executive compensation and does not signal a change in company fundamentals or strategy. The CEO retains significant ownership.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by the CEO following RSU vesting. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The CEO retains a substantial stake, indicating continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's investment thesis.

Keywords

Aurinia Pharmaceuticals, AUPH, Peter Greenleaf, CEO, Director, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting, Beneficial Ownership